EcoR1 Makes a Timely Bet

Mirati’s deal with Bristol Myers Squibb came too late to save life sciences funds, which suffered through another rough month in September.


Getty Images

Now this is what you call market timing.

Life sciences hedge fund EcoR1 Capital disclosed that as of September 22 it had initiated a stake of nearly 5.75 million shares of Mirati Therapeutics, making it the second-largest shareholder, with about 9.8 percent of the commercial-stage oncology company’s shares.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.